Combination treatment with chemotherapy and trastuzumab is now standard therapy for the first-line treatment of women with HER2-overexpressing metastatic breast cancer. Combination therapy with trastuzumab has been shown to increase response rates, time to progression, quality of life, and overall survival for such patients. Several combination regimens have been developed, and newer combination regimens have recently been reported and are being studied in ongoing clinical trials. Newer trastuzumab-based regimens include triplet combinations with taxanes and platinum salts and regimens combining other innovative therapies. Among the increasing array of available combinations, several have proven appropriate for first-line therapy. To date, the optimal combination region has not been defined. Moreover, several questions remain regarding best scheduling, treatment duration, and use of trastuzumab at disease progression. This review briefly outlines the evolving role of trastuzumab in the treatment of HER2-overexpressing metastatic breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3816/cbc.2003.n.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Clin Cancer Res
January 2025
The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) which is HER2-positive (immunohistochemistry [IHC] score of 3+ or ISH positivity) or HER2-low (IHC score of 1+ or IHC 2+/ISH negative), as well as for HER2-positive gastric cancer, HER2-mutant lung cancer, and HER2 overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 receptor status might change following T-DXd therapy.
Design: We retrospectively reviewed patients with MBC who received T-DXd at The University of Texas MD Anderson Cancer Center.
Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study.
BMC Womens Health
December 2024
The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, 315000, China.
Background: This study aimed to construct, evaluate, and validate nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) prediction in patients with HER2- overexpressing (HER2+) metastatic breast cancer (MBC).
Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to select female patients diagnosed with HER2 + MBC between 2010 and 2015. These patients were distributed into training and validation groups (7:3 ratio).
Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies.
BMC Cancer
December 2024
Department of Clinical Therapeutics, Medical School, Alexandra Hospital, 11528, Athens, Greece.
Article Synopsis
- HER2 overexpression is a significant target for treating gynecological cancers, and Trastuzumab-Deruxtecan (T-DXd) has shown notable effectiveness against these cancers, particularly in ovarian, endometrial, and cervical malignancies.
- A study was conducted at the Alexandra Hospital in Athens involving 10 patients with HER2-positive gynecological cancers who were treated with T-DXd, administered intravenously every 3 weeks.
- Results indicated a median progression-free survival of 5.4 months, with 5 patients achieving a partial response, highlighting T-DXd's potential as a treatment option even for patients with prior therapies.
Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature.
World J Clin Oncol
October 2024
Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 510000, Shandong Province, China.
Background: In patients with human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer (GC), the combination of HER2 targeting and a standard first-line chemotherapy regimen has been demonstrated to significantly improve their prognosis. However, in a proportion of patients, cancer progresses within a short period of time, and there is currently no standard treatment after disease progression.
Case Summary: This study presents a case of a 51-year-old male with advanced GC who underwent radical resection (Billroth type II subtotal gastrectomy and gastrojejunostomy) and resection of liver metastases.
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
J Exp Clin Cancer Res
August 2024
Section of Translational Breast Cancer Research and Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Article Synopsis
- Anti-HER2 therapies like trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) have improved outcomes for patients with HER2+ metastatic breast cancer, but resistance to these treatments poses a significant challenge without established follow-up therapies.
- The study examined genetic changes in breast cancer patients after anti-HER2 therapy and developed resistant cancer cell lines to explore mechanisms of resistance and identify potential targets to boost the effectiveness of T-DXd.
- It was discovered that resistance might occur due to reduced HER2 expression and increased activity of DNA repair genes, suggesting that targeting DNA repair pathways could enhance the efficacy of T-DXd in resistant cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!